Beacon Pointe Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-200
Closed -$5.6K 1289
2024
Q2
$5.6K Buy
+200
New +$5.51K ﹤0.01% 1265
2024
Q1
Sell
-100
Closed -$2.88K 1397
2023
Q4
$2.88K Hold
100
﹤0.01% 1316
2023
Q3
$3.32K Buy
+100
New +$3.54K ﹤0.01% 1330

Other funds holding PFE

Beacon Pointe Advisors's PFE Position: Q1 2026 in Review

Beacon Pointe Advisors increased its Pfizer (PFE) stake by 22% in Q1 2026, buying an estimated $5.69M and bringing the position to 1,174,349 shares worth $33M. The position accounts for 0.17% of the portfolio, ranked #126.

Beacon Pointe Advisors first reported a position in PFE in Q4 2018 and has held it in 30 quarters since. The position peaked at $44.8M in Q3 2023. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Beacon Pointe Advisors held 1,174,349 shares of Pfizer worth $33M as of Q1 2026.
  • Beacon Pointe Advisors bought 213,796 Pfizer shares in Q1 2026, an estimated $5.69M.
  • Pfizer made up 0.17% of Beacon Pointe Advisors's portfolio in Q1 2026, its #126 holding.
  • Beacon Pointe Advisors first reported a position in Pfizer in Q4 2018 and has held it in 30 quarters since.
  • Beacon Pointe Advisors's Pfizer position peaked at $44.8M in Q3 2023.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.